Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  1/24/2018
Stanford Cancer Center
mi
from
Stanford, CA
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 1/24/2018
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  1/24/2018
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 1/24/2018
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Status: Enrolling
Updated:  1/25/2018
University of California at San Francisco
mi
from
San Francisco, CA
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Status: Enrolling
Updated: 1/25/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  1/25/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 1/25/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Whittier, CA
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Somerville, NJ
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Somerville, NJ
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Goldsboro, NC
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Canton, OH
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Canton, OH
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Bend, OR
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Watertown, SD
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Watertown, SD
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
mi
from
Resistencia,
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
mi
from
Resistencia,
Click here to add this to my saved trials
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated:  1/25/2018
Clinical Research Facility
mi
from
Rochester, MN
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Status: Enrolling
Updated: 1/25/2018
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
Status: Enrolling
Updated:  1/25/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
Status: Enrolling
Updated: 1/25/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Status: Enrolling
Updated:  1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Status: Enrolling
Updated: 1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
Weill-Cornell Medical College
mi
from
New York, NY
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
University of Chicago
mi
from
Chicago, IL
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated:  1/26/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Status: Enrolling
Updated: 1/26/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  1/26/2018
University of Chicago
mi
from
Chicago, IL
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 1/26/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  1/26/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 1/26/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  1/26/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 1/26/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  1/26/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 1/26/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Mayo Clinic Arizona - Cancer Clinical Research Unit
mi
from
Scottsdale, AZ
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Mayo Clinic Arizona - Cancer Clinical Research Unit
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Stanford Cancer Center - Stanford University
mi
from
Stanford, CA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Stanford Cancer Center - Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
mi
from
New York, NY
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Oregon Health and Science University
mi
from
Portland, OR
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Virginia Health System
mi
from
Charlottesville, VA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
The Mayo Clinic
mi
from
Rochester, MN
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom
Status: Enrolling
Updated:  1/29/2018
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom
Status: Enrolling
Updated: 1/29/2018
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/30/2018
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/30/2018
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
A Phase I Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated:  1/30/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
A Phase I Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated: 1/30/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Mountain States Tumor Institute at St. Luke's Regional Medical Center
mi
from
Boise, ID
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Mountain States Tumor Institute at St. Luke's Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cancer Center of Kansas-Independence
mi
from
Independence, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Southwest Medical Center
mi
from
Liberal, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Southwest Medical Center
mi
from
Liberal, KA
Click here to add this to my saved trials
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated:  1/31/2018
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II
Status: Enrolling
Updated: 1/31/2018
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials